Bill Text: CA AB2095 | 2015-2016 | Regular Session | Amended

---

Bill Title: Medi-Cal: prescriptions.

Spectrum: Partisan Bill (Republican 1-0)

Status: (Failed) 2016-11-30 - From committee without further action. [AB2095 Detail]

Download: California-2015-AB2095-Amended.html

---

BILL NUMBER: AB 2095	AMENDED
	BILL TEXT

	AMENDED IN ASSEMBLY  MARCH 18, 2016

INTRODUCED BY   Assembly Member Travis Allen

                        FEBRUARY 17, 2016

   An act relating to  economic development.  
Medi-Cal. 



	LEGISLATIVE COUNSEL'S DIGEST


   AB 2095, as amended, Travis Allen.  Economic development.
  Medi-Cal: prescriptions.  
   Existing law establishes the Medi-Cal program, administered by the
State Department of Health Care Services, under which health care
services are provided to qualified, low-income persons. The Medi-Cal
program is, in part, governed and funded by federal Medicaid Program
provisions.  
   This bill would require the Legislative Analyst's Office to
conduct or cause to be conducted a study comparing the purchase or
administration of brand name prescription medications through the
Medi-Cal program to the purchase or administration of biosimilars
through the Medi-Cal program, as specified. The bill would require
the study to cover the 2013-14 and 2014-15 fiscal years and to be
completed on or before January 1, 2018.  
   Existing law creates various state agencies and authorizes certain
of those agencies to regulate the operations of businesses. Existing
law, until January 1, 2018, authorizes cities and counties to
establish capital investment incentive programs to attract large
manufacturing facilities to invest in their communities and to
encourage industries, such as high technology, aerospace, automotive,
biotechnology, software, and environmental sources and others, to
locate and invest in those facilities in California. 

   This bill would express the intent of the Legislature to enact
legislation that would enhance and advance opportunities for
California's biotechnology industry. 
   Vote: majority. Appropriation: no. Fiscal committee:  no
  yes  . State-mandated local program: no.


THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS:

   SECTION 1.    The Legislative Analyst's Office shall
conduct or cause to be conducted a study comparing the purchase or
administration of brand name prescription medications through the
Medi-Cal program to the purchase or administration of biosimilars
through the Medi-Cal program. The study shall cover the 2013-14 and
2014-15 fiscal years and shall be completed on or before January 1,
2018. The study shall breakdown the information by the age,
ethnicity, and gender of the Medi-Cal recipients who purchase those
medications or to whom the medications are administered. 

  SECTION 1.    It is the intent of the Legislature
to enact legislation that would enhance and expand opportunities for
California's biotechnology industry.